Chemomab Therapeutics (CMMB) Set to Release Earnings on Friday

Chemomab Therapeutics (NASDAQ:CMMB) is expected to announce its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Chemomab Therapeutics to post earnings of ($0.01) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.

Chemomab Therapeutics (NASDAQ:CMMB) last released its earnings results on Thursday, August 20th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.12).

Chemomab Therapeutics Price Performance

Shares of NASDAQ:CMMB opened at $1.23 on Thursday. The business’s 50 day moving average price is $1.84 and its 200-day moving average price is $1.75. The firm has a market capitalization of $8.92 million, a PE ratio of -0.58 and a beta of 0.80. Chemomab Therapeutics has a 1 year low of $0.92 and a 1 year high of $2.99.

Analyst Ratings Changes

Several research analysts recently commented on CMMB shares. Weiss Ratings raised Chemomab Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 16th. Wall Street Zen raised shares of Chemomab Therapeutics to a “hold” rating in a research note on Saturday, October 3rd. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company focused on developing therapies for diseases driven by fibrosis and inflammation. The company’s research platform is centered on chemokine biology, with the goal of developing treatments for conditions that currently have limited therapeutic options.

Chemomab’s lead product candidate is CM-101, a humanized monoclonal antibody designed to neutralize CCL24, a signaling protein believed to contribute to chronic inflammation and tissue scarring.